Javier
Ampuero Herrojo
Publicaciones en las que colabora con Javier Ampuero Herrojo (22)
2024
-
FIB-4 score as a predictor of COVID-19-related severity in hospitalized patients
Revista Espanola de Enfermedades Digestivas, Vol. 116, Núm. 9, pp. 465-471
-
Fibroblast growth factor 21 is a hepatokine involved in MASLD progression
United European Gastroenterology Journal, Vol. 12, Núm. 8, pp. 1056-1068
-
Letter to the Editor: Serum Identification of At-Risk MASH: The Metabolomics-Advanced Steatohepatitis Fibrosis Score (MASEF)
Hepatology
-
One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population
United European Gastroenterology Journal, Vol. 12, Núm. 7, pp. 919-929
-
Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia
-
Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease
Gut, Vol. 73, Núm. 5, pp. 825-834
-
Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
Hepatology, Vol. 79, Núm. 1, pp. 135-148
-
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis
Journal of Gastroenterology, Vol. 59, Núm. 7, pp. 586-597
2023
-
AEEH «Consensus about detection and referral of hidden prevalent liver diseases»
Gastroenterologia y Hepatologia, Vol. 46, Núm. 3, pp. 236-247
-
Predicting liver-related events in NAFLD: A predictive model
Hepatology (Baltimore, Md.), Vol. 78, Núm. 4, pp. 1240-1251
-
Role of EpCAM+ CD133+ extracellular vesicles in steatosis to steatohepatitis transition in NAFLD
Liver International, Vol. 43, Núm. 9, pp. 1909-1919
2022
-
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?
Gut, Vol. 71, Núm. 2, pp. 382-390
-
Liver injury in non-alcoholic fatty liver disease is associated with urea cycle enzyme dysregulation
Scientific Reports, Vol. 12, Núm. 1
-
Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology
Liver International, Vol. 42, Núm. 8, pp. 1783-1792
2021
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
-
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease
Journal of Hepatology, Vol. 75, Núm. 4, pp. 786-794
2020
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD)
Revista Española de Enfermedades Digestivas, Vol. 111, Núm. 4, pp. 264-269